Steven Kahn
Seattle, WANPI 1104901800
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Merck at 29.9% of the total.
Across 313 payments — averaging $1412.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$132K
- Eli Lilly$103K
- Novo Nordisk AS$70K
- Boehringer Ingelheim B.v.$42K
- Novo Nordisk$27K
- Amgen$16K
- plus $51K from 12 others
Across 31 payments — averaging $3222.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$49K
- Amgen$32K
- Eli Lilly$18K
- Corcept Therapeutics$1K
What the payments were for
- Consulting fees$207,26947%
- Speaking & faculty fees$78,37618%
- Travel & lodging$151,53134%
- Food & beverage$5,0021%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 93 | $132,218 |
| Eli Lilly | 103 | $102,918 |
| Novo Nordisk AS | 23 | $70,236 |
| Boehringer Ingelheim B.v. | 10 | $41,693 |
| Novo Nordisk | 15 | $27,495 |
| Amgen | 17 | $16,442 |
| Pfizer | 8 | $13,089 |
| Boehringer Ingelheim South Africa (pty) Ltd | 11 | $11,583 |
| Boehringer Ingelheim MENA (scientific Office) Fz-llc | 4 | $9,500 |
| Boehringer Ingelheim Korea LTD. | 1 | $3,700 |
| Boehringer Ingelheim Hong Kong Ltd. | 1 | $3,500 |
| Boehringer Ingelheim Singapore Pte. Ltd. | 1 | $3,330 |
| Boehringer Ingelheim (phil.) Inc. | 1 | $3,300 |
| Boehringer Ingelheim International GmbH | 9 | $1,676 |
| Corcept Therapeutics | 13 | $1,289 |
| Zealand Pharma US, Inc. | 1 | $189 |
| AstraZeneca | 1 | $58 |
| Janssen Scientific Affairs, LLC | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.